MannKind (MNKD)
(Delayed Data from NSDQ)
$6.60 USD
-0.10 (-1.49%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
MannKind Corporation [MNKD]
Reports for Purchase
Showing records 1 - 20 ( 229 total )
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Focus Turns to Orphan Lung Pipeline Afrezza w/ Tyvaso DPI Launch Underway
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Tyvaso DPI Royalty Monetization Magnitude Shines Light on Valuation Disconnect, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Tyvaso DPI Royalty Deal Pads Balance Sheet, Underscores Blockbuster Potential
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Federal Circuit Affirms ''793 PTAB Decision; Tyvaso DPI''s Dominance to Persist
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
First-Time Profitability Milestone; Growth and Execution Across the Business; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Q3: Tyvaso DPI Continues to Drive Growth; Orphan Drug Pipeline Trials in H1:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Don''t Call It a Comeback...Initiating at OP and $10 PT
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
REMINDER: Wedbush PacGrow Healthcare Bus Trip to Tyvaso DPI Facility in CT
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Don''t Call It A Comeback...Initiating at OP and $10 PT
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Breakeven Secured Ahead of Schedule; Tyvaso DPI Outperforming; Raise to $7.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
On Cusp of Positive Cash Flow; Material Upside From Current Business Alone, Plus Pipeline Optionality; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
4Q22: Tyvaso DPI Impressive Launch Ramp Continues; Afrezza Outperforming; Raise to $7 Before Adding Pipeline Value
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
3Q22: Cooking With Gas as Tyvaso DPI Jumps Out of the Gates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Breathing Easy With Tyvaso DPI Approval and V-Go Accretive Bolt-On Product Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Tyvaso DPI Safety Fear and Stock Pullback Likely an Overreaction; Reiterate Buy; Tweak Target to $6 on Lower Afrezza
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O